Does accumulation of ketoisocaproic acid, ketoisovaleric acid, and keto-beta-methylvaleric acid reflect impaired branched-chain amino acid oxidation?

Biochemical basis of BCKA accumulation

• Enzymatic Bottleneck: Under normal physiological conditions, the mitochondrial branched-chain $\alpha$-ketoacid dehydrogenase (BCKDH) multienzyme complex catalyzes the irreversible, rate-limiting oxidative decarboxylation of branched-chain $\alpha$-keto acids (BCKAs): ketoisocaproic acid (KIC), keto-$\beta$-methylvaleric acid (KMV), and ketoisovaleric acid (KIV).
• Direct Accumulation: When BCKDH activity is impaired—either through genetic mutations or post-translational phosphorylation and inhibition—the metabolic breakdown of these substrates is blocked. This enzymatic block directly leads to the concurrent accumulation of KIC, KIV, and KMV in tissues, plasma, and urine.

Downstream metabolic and mitochondrial effects

• Mitochondrial Pyruvate Carrier (MPC) Inhibition: Accumulated BCKAs directly inhibit the MPC in hepatocytes. This inhibition suppresses mitochondrial pyruvate uptake, disrupting gluconeogenesis and glucose homeostasis.
• Suppressed Respiratory Activity: Elevated cellular concentrations of BCKAs lead to a direct decrease in mitochondrial oxygen consumption and depress respiratory activity, particularly within skeletal muscle cells.
• Pathological Signatures: Reduced BCKDH activity and the resulting accumulation of these three BCKAs are established metabolic signatures associated with insulin resistance, type 2 diabetes, and heart failure, reflecting systemic mitochondrial and oxidative stress.

Bottom line

• The accumulation of ketoisocaproic acid, ketoisovaleric acid, and keto-$\beta$-methylvaleric acid serves as a direct, biochemically verified signature of impaired BCAA oxidation at the mitochondrial BCKDH step, which further compromises cellular energy dynamics by suppressing pyruvate transport and mitochondrial respiration.